(ARE) Alexandria Real Estate - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0152711091
Laboratory, Campus, Office, Campus Amenities, Services
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 6.30% |
| Yield on Cost 5y | 3.41% |
| Yield CAGR 5y | 1.10% |
| Payout Consistency | 95.6% |
| Payout Ratio | 15.6% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 31.0% |
| Value at Risk 5%th | 47.8% |
| Relative Tail Risk | -6.10% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.18 |
| Alpha | -51.89 |
| CAGR/Max DD | -0.36 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.875 |
| Beta | 0.762 |
| Beta Downside | 1.098 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.80% |
| Mean DD | 35.29% |
| Median DD | 31.05% |
Description: ARE Alexandria Real Estate January 03, 2026
Alexandria Real Estate Equities (NYSE: ARE) is an S&P 500-listed REIT that specializes in purpose-built life-science campuses across major U.S. innovation hubs, including Greater Boston, the Bay Area, San Diego, Seattle, Maryland’s Bio-Park, the Research Triangle, and New York City. Founded in 1994, the company has positioned itself as the longest-tenured owner, operator, and developer of “Megacampus” ecosystems that foster collaborative research and commercial development.
Key performance indicators show strong fundamentals: occupancy across its portfolio remained above 96% in FY 2023, while funds-from-operations (FFO) grew roughly 10% year-over-year, driven by rising lease rates and a low vacancy environment. The life-science sector benefits from sustained macro-drivers such as a 5%-plus annual increase in U.S. biotech R&D spending and robust capital formation, which underpin demand for high-quality lab and office space.
For a deeper quantitative view, consider reviewing ValueRay’s detailed metrics on ARE’s valuation and cash-flow trends.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-413.1m TTM) > 0 and > 6% of Revenue (6% = 179.7m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 0.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -84.52% (prev -55.26%; Δ -29.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 1.38b > Net Income -413.1m (YES >=105%, WARN >=100%) |
| Net Debt (13.38b) to EBITDA (1.25b) ratio: 10.74 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (170.1m) change vs 12m ago -1.12% (target <= -2.0% for YES) |
| Gross Margin 68.94% (prev 70.57%; Δ -1.63pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 7.90% (prev 7.87%; Δ 0.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.52 (EBITDA TTM 1.25b / Interest Expense TTM 216.7m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 56.77
| 1. Piotroski 2.50pt |
| 2. FCF Yield 6.03% |
| 3. FCF Margin 45.93% |
| 4. Debt/Equity 0.84 |
| 5. Debt/Ebitda 10.74 |
| 6. ROIC - WACC (= -4.00)% |
| 7. RoE -2.39% |
| 8. Rev. Trend 88.94% |
| 9. EPS Trend -43.56% |
What is the price of ARE shares?
As of January 21, 2026, the stock is trading at USD 57.52 with a total of 2,615,414 shares traded.
Over the past week, the price has changed by +5.27%, over one month by +20.05%, over three months by -23.93% and over the past year by -40.45%.
Over the past week, the price has changed by +5.27%, over one month by +20.05%, over three months by -23.93% and over the past year by -40.45%.
Is ARE a buy, sell or hold?
Alexandria Real Estate has received a consensus analysts rating of 3.54.
Therefor, it is recommend to hold ARE.
- Strong Buy: 3
- Buy: 1
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ARE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 57.9 | 0.7% |
| Analysts Target Price | 57.9 | 0.7% |
| ValueRay Target Price | 48.8 | -15.2% |
ARE Fundamental Data Overview January 15, 2026
P/E Forward = 16.6945
P/S = 3.0876
P/B = 0.5675
P/EG = 844.2
Revenue TTM = 3.00b USD
EBIT TTM = -112.7m USD
EBITDA TTM = 1.25b USD
Long Term Debt = 12.04b USD (from longTermDebt, last quarter)
Short Term Debt = 1.55b USD (from shortTermDebt, last quarter)
Debt = 13.96b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.38b USD (from netDebt column, last quarter)
Enterprise Value = 22.82b USD (9.44b + Debt 13.96b - CCE 579.5m)
Interest Coverage Ratio = -0.52 (Ebit TTM -112.7m / Interest Expense TTM 216.7m)
EV/FCF = 16.59x (Enterprise Value 22.82b / FCF TTM 1.38b)
FCF Yield = 6.03% (FCF TTM 1.38b / Enterprise Value 22.82b)
FCF Margin = 45.93% (FCF TTM 1.38b / Revenue TTM 3.00b)
Net Margin = -13.79% (Net Income TTM -413.1m / Revenue TTM 3.00b)
Gross Margin = 68.94% ((Revenue TTM 3.00b - Cost of Revenue TTM 930.5m) / Revenue TTM)
Gross Margin QoQ = 68.18% (prev 69.56%)
Tobins Q-Ratio = 0.61 (Enterprise Value 22.82b / Total Assets 37.38b)
Interest Expense / Debt = 0.39% (Interest Expense 54.9m / Debt 13.96b)
Taxrate = 21.0% (US default 21%)
NOPAT = -89.1m (EBIT -112.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.27 (Total Current Assets 945.2m / Total Current Liabilities 3.48b)
Debt / Equity = 0.84 (Debt 13.96b / totalStockholderEquity, last quarter 16.64b)
Debt / EBITDA = 10.74 (Net Debt 13.38b / EBITDA 1.25b)
Debt / FCF = 9.72 (Net Debt 13.38b / FCF TTM 1.38b)
Total Stockholder Equity = 17.29b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.09% (Net Income -413.1m / Total Assets 37.38b)
RoE = -2.39% (Net Income TTM -413.1m / Total Stockholder Equity 17.29b)
RoCE = -0.38% (EBIT -112.7m / Capital Employed (Equity 17.29b + L.T.Debt 12.04b))
RoIC = -0.29% (negative operating profit) (NOPAT -89.1m / Invested Capital 30.35b)
WACC = 3.70% (E(9.44b)/V(23.40b) * Re(8.72%) + D(13.96b)/V(23.40b) * Rd(0.39%) * (1-Tc(0.21)))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.28%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈1.33b ; Y1≈874.8m ; Y5≈399.1m
Fair Price DCF = N/A (negative equity: EV 12.72b - Net Debt 13.38b = -658.8m; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: -43.56 | EPS CAGR: -10.06% | SUE: -0.60 | # QB: 0
Revenue Correlation: 88.94 | Revenue CAGR: 7.43% | SUE: -0.15 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.19 | Chg30d=-0.076 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.09 | Chg30d=-0.283 | Revisions Net=+1 | Growth EPS=+95.0% | Growth Revenue=-7.5%
P/S = 3.0876
P/B = 0.5675
P/EG = 844.2
Revenue TTM = 3.00b USD
EBIT TTM = -112.7m USD
EBITDA TTM = 1.25b USD
Long Term Debt = 12.04b USD (from longTermDebt, last quarter)
Short Term Debt = 1.55b USD (from shortTermDebt, last quarter)
Debt = 13.96b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.38b USD (from netDebt column, last quarter)
Enterprise Value = 22.82b USD (9.44b + Debt 13.96b - CCE 579.5m)
Interest Coverage Ratio = -0.52 (Ebit TTM -112.7m / Interest Expense TTM 216.7m)
EV/FCF = 16.59x (Enterprise Value 22.82b / FCF TTM 1.38b)
FCF Yield = 6.03% (FCF TTM 1.38b / Enterprise Value 22.82b)
FCF Margin = 45.93% (FCF TTM 1.38b / Revenue TTM 3.00b)
Net Margin = -13.79% (Net Income TTM -413.1m / Revenue TTM 3.00b)
Gross Margin = 68.94% ((Revenue TTM 3.00b - Cost of Revenue TTM 930.5m) / Revenue TTM)
Gross Margin QoQ = 68.18% (prev 69.56%)
Tobins Q-Ratio = 0.61 (Enterprise Value 22.82b / Total Assets 37.38b)
Interest Expense / Debt = 0.39% (Interest Expense 54.9m / Debt 13.96b)
Taxrate = 21.0% (US default 21%)
NOPAT = -89.1m (EBIT -112.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.27 (Total Current Assets 945.2m / Total Current Liabilities 3.48b)
Debt / Equity = 0.84 (Debt 13.96b / totalStockholderEquity, last quarter 16.64b)
Debt / EBITDA = 10.74 (Net Debt 13.38b / EBITDA 1.25b)
Debt / FCF = 9.72 (Net Debt 13.38b / FCF TTM 1.38b)
Total Stockholder Equity = 17.29b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.09% (Net Income -413.1m / Total Assets 37.38b)
RoE = -2.39% (Net Income TTM -413.1m / Total Stockholder Equity 17.29b)
RoCE = -0.38% (EBIT -112.7m / Capital Employed (Equity 17.29b + L.T.Debt 12.04b))
RoIC = -0.29% (negative operating profit) (NOPAT -89.1m / Invested Capital 30.35b)
WACC = 3.70% (E(9.44b)/V(23.40b) * Re(8.72%) + D(13.96b)/V(23.40b) * Rd(0.39%) * (1-Tc(0.21)))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.28%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈1.33b ; Y1≈874.8m ; Y5≈399.1m
Fair Price DCF = N/A (negative equity: EV 12.72b - Net Debt 13.38b = -658.8m; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: -43.56 | EPS CAGR: -10.06% | SUE: -0.60 | # QB: 0
Revenue Correlation: 88.94 | Revenue CAGR: 7.43% | SUE: -0.15 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.19 | Chg30d=-0.076 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.09 | Chg30d=-0.283 | Revisions Net=+1 | Growth EPS=+95.0% | Growth Revenue=-7.5%
Additional Sources for ARE Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle